MiR-132, which is highly expressed in cirrhotic patients, is also an important promoter of hepatic fibrosis, as evidenced by an anti-miR-132 approach in a mouse model of fibrosis (CCL4-treated mice). The gene discussed is CCL4; the disease is Hepatic fibrosis.